Controversial abortion drug RU486 is set to become much cheaper following a recommendation that it be publicly subsidised.

The Pharmaceutical Benefits Advisory Committee is expected to release its recommendations on the drug on Friday, including whether it should be made available on the Pharmaceutical Benefits Scheme (PBS).

PBS-listed drugs are cheaper for consumers, effectively making them more widely available.

Some reports suggest the price of RU486 could drop by hundreds of dollars.